Glycominds Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

Glycominds General Information

Description

Provider of laboratory research services intended to validate serum bio-marker tests for inflammatory bowel disease. The company develops and commercializes gastrointestinal disease management tools and services, enabling physicians to help identify patients who have celiac disease and inflammatory bowel diseases to achieve early, non-invasive and cost-effective diagnosis.

Contact Information

Website
www.glycominds.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Alon Building, Global Park
  • P.O.Box 12
  • Redwood City, CA 94063
  • United States
+1 (866)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Diagnostic Equipment
Parent Company
Medivie Therapeutic
Corporate Office
  • Alon Building, Global Park
  • P.O.Box 12
  • Redwood City, CA 94063
  • United States
+1 (866)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycominds Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Apr-2014 Completed Generating Revenue
5. IPO 23-Feb-2011 Completed Generating Revenue
4. Later Stage VC 01-Jul-2009 Completed Generating Revenue
3. Later Stage VC 01-Oct-2006 Completed Generating Revenue
2. Later Stage VC 01-Jan-2005 $1M $8.1M Completed Generating Revenue
1. Early Stage VC (Series A) 14-Nov-2001 $7.1M $7.1M Completed Startup
To view Glycominds’s complete valuation and funding history, request access »

Glycominds Patents

  • 106

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • Pending

  • Expiring in next 12 mo

Glycominds Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11480569-B2 Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis Active 01-Dec-2016
US-20190331679-A1 Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis Active 01-Dec-2016
EP-2475993-A2 Method for diagnosing multiple sclerosis Inactive 09-Sep-2009
WO-2011030217-A2 Method for diagnosing multiple sclerosis Inactive 09-Sep-2009
WO-2011030217-A3 Method for diagnosing multiple sclerosis Inactive 09-Sep-2009 G01N33/564
To view Glycominds’s complete patent history, request access »

Glycominds Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycominds Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
BRM Group Venture Capital Minority
Coronis Partners Corporation Minority
Hunza Ventures Venture Capital Minority
Millennium Materials Technologies Fund Venture Capital Minority
Proxima Investments Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Glycominds Acquisitions (1)

Glycominds’s most recent deal was a Reverse Merger with Medivie Therapeutic. The deal was made on 11-Mar-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Medivie Therapeutic 11-Mar-2014 Reverse Merger Other Healthcare Services
To view Glycominds’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Glycominds FAQs

  • When was Glycominds founded?

    Glycominds was founded in 1999.

  • Where is Glycominds headquartered?

    Glycominds is headquartered in Redwood City, CA.

  • What is the size of Glycominds?

    Glycominds has 5 total employees.

  • What industry is Glycominds in?

    Glycominds’s primary industry is Laboratory Services (Healthcare).

  • Is Glycominds a private or public company?

    Glycominds is a Private company.

  • What is Glycominds’s current revenue?

    The current revenue for Glycominds is .

  • How much funding has Glycominds raised over time?

    Glycominds has raised $13.7M.

  • Who are Glycominds’s investors?

    BRM Group, Coronis Partners, Hunza Ventures, Millennium Materials Technologies Fund, and Proxima Investments are 5 of 7 investors who have invested in Glycominds.

  • When was Glycominds acquired?

    Glycominds was acquired on 01-Apr-2014.

  • Who acquired Glycominds?

    Glycominds was acquired by Medivie Therapeutic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process